| Market Capitalization (Millions $) |
3 |
| Shares
Outstanding (Millions) |
17 |
| Employees |
75 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-28 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Unity Biotechnology Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California, with a mission to develop transformative medicines that extend human healthspan by preventing, halting or reversing disease mechanisms associated with aging. The company was founded in 2011 by a team of veteran biotech entrepreneurs and scientists, including Nathaniel David, Aubrey de Grey, Judith Campisi, Keith Leonard and Robert Nelsen, with the aim of targeting senescent cells, which are cells that have stopped dividing due to age or damage, but remain metabolically active, secreting molecules that promote inflammation, tissue or organ dysfunction, and cancer.
Unity Biotechnology's proprietary platform is based on deep knowledge and expertise in cellular senescence and genomics. The company employs a multidisciplinary approach that combines bioinformatics, high-throughput screening, medicinal chemistry, preclinical and clinical development to identify, design and optimize selective senolytic drugs that selectively kill senescent cells or modulate their pro-inflammatory or pro-survival signaling pathways. Unity Biotechnology's pipeline focuses on multiple age-related diseases, including osteoarthritis, diabetic nephropathy, age-related macular degeneration, Alzheimer's disease, and cancer.
Unity Biotechnology's lead program is UBX0101, which is a small-molecule inhibitor of the MDM2/p53 pathway that regulates the survival of cells undergoing senescence in osteoarthritic joints. UBX0101 has completed a Phase 1 clinical trial in patients with moderate to severe knee osteoarthritis and demonstrated favorable safety, tolerability and efficacy. The Phase 2 study of UBX0101 for knee osteoarthritis is currently ongoing, with top-line data expected in 202
Unity Biotechnology also has several other programs in preclinical and clinical development, including UBX1325 for diabetic nephropathy, UBX1967 for age-related macular degeneration, and UBX1917 for senescence-related cancers. The company has collaborations with several leading academic institutions and industry partners, including the Buck Institute for Research on Aging, the Mayo Clinic, and Ono Pharmaceutical Co.
Unity Biotechnology has raised over $700 million in funding from leading healthcare investors, including ARCH Venture Partners, Venrock, Fidelity, Baillie Gifford, and Independence Blue Cross. The company went public in 2018 and is traded on NASDAQ under the ticker symbol "UBX". The company has a broad intellectual property portfolio covering its technology platform and drug candidates.
Company Address: 285 East Grand Ave. South San Francisco 94080 CA
Company Phone Number: 416-1192 Stock Exchange / Ticker: NASDAQ UBX
|
0.05%